12.06.2018 | Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR CO.DON AG (ISIN: DE000A1K0227), Aktuell

Berlin / Teltow, 12 June 2018, 18:02 p.m. - CO.DON AG is in final stage negotiations with Haemo Pharma GmbH concerning the exclusive distribution in Austria of Spherox, a cell-based pharmaceutical for which central EU marketing authorisation has been granted. The parties signed a term sheet today governing the key elements of their potential collaboration and of a distribution agreement, which now has to be refined in detail. By signing the distribution agreement, with an initial term of 5 years, CO.DON AG would generate at least a guaranteed cash inflow in the first two years of (all in all) approximately 17% of the revenue in the financial year 2017 (revenue in 2017: kEUR 5,964). From 2020, cash inflow will depend on the development of the state reimbursement situation. The distribution agreement is subject to the approval of the Supervisory Board of CO.DON AG.

Notifier:

Matthias Meißner, M.A.

Director Investor Relations / Public Relations

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de

Attachments

  • Original document
  • Permalink

Disclaimer

co.don AG published this content on 12 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 June 2018 16:17:02 UTC